Alpha Or Leukocyte Patents (Class 424/85.7)
-
Publication number: 20120076755Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B-W??(I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: October 4, 2011Publication date: March 29, 2012Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Lu Ying, Hui Cao, Yat Sun Or
-
Publication number: 20120076756Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: October 4, 2011Publication date: March 29, 2012Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Lu Ying, Yat Sun Or
-
Publication number: 20120076758Abstract: The present invention relates to compositions comprising antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV), and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV), infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.Type: ApplicationFiled: April 29, 2011Publication date: March 29, 2012Applicant: WASHINGTON UNIVERSITYInventors: MICHAEL DIAMOND, THEODORE OLIPHANT, CHRISTOPHER MICHAEL DOANE
-
Patent number: 8143214Abstract: Protein-polymer conjugates are described. Also described are a method for preparing a protein-polymer conjugate and its use in treating hepatitis B virus or hepatitis C virus infection.Type: GrantFiled: August 15, 2008Date of Patent: March 27, 2012Assignee: PharmaEssentia Corp.Inventor: Ko-Chung Lin
-
Publication number: 20120070408Abstract: The invention provides methods of treating lupus in a patient with an anti-CD52 antibody. Also includes are methods of increasing infiltration of regulatory T cells to affected sides of the patient's body, methods of reducing urine protein and/or albumin levels and methods of depleting lymphocytes to alleviate lupus symptoms.Type: ApplicationFiled: May 13, 2010Publication date: March 22, 2012Applicant: GENZYME CORPORATIONInventors: Johanne M. Kaplan, Bruce L. Roberts, William M. Siders
-
Publication number: 20120070417Abstract: The invention relates to pharmaceutical compositions that contain a calcium salt as an active ingredient and also comprise another anti-influenza agent, and to methods for treating or preventing influenza virus infection.Type: ApplicationFiled: March 26, 2010Publication date: March 22, 2012Applicant: PULMATRIX, INC.Inventors: Richard Batycky, David L. Hava, Robert W. Clarke, Michal M. Lipp
-
Publication number: 20120070407Abstract: There is disclosed the use of a composition for promoting neuronal growth of neurons in tissues of the central or peripheral nervous system. There is also disclosed a method for inducing proliferation or differentiation of neuronal cells.Type: ApplicationFiled: March 29, 2010Publication date: March 22, 2012Inventors: Michel Maurice Jacques Lazdunski, Catherine Louise Heurteaux, David Picard
-
Publication number: 20120070416Abstract: The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: September 20, 2011Publication date: March 22, 2012Inventors: Yat Sun Or, Jun Ma, Guoqiang Wang, Jiang Long, Bin Wang
-
Patent number: 8137661Abstract: The invention relates to controlled release formulations comprising a microparticle comprising a biodegradable polymer and one or more interferon compounds and methods of using the formulations.Type: GrantFiled: July 25, 2008Date of Patent: March 20, 2012Assignee: Biolex Therapeutics, Inc.Inventors: David Gelvin Spencer, Jr., John Elliott Humphries, Leonardus Gerardus Jozef De Leede, Rudolf Verrijk
-
Publication number: 20120064037Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.Type: ApplicationFiled: September 30, 2011Publication date: March 15, 2012Inventors: Philip E. Thorpe, M. Melina Soares, Sophia Ran
-
Publication number: 20120064034Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.Type: ApplicationFiled: November 10, 2011Publication date: March 15, 2012Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: ROBERT EDWARD BABINE, SHU HUI CHEN, IVAN COLLADO, CRISTINA GARCIA-PAREDES, JOHN IRVIN GLASS, DEQI GUO, LING JIN, JASON ERIC LAMAR, RAYMOND SAMUEL PARKER, III, NANCY JUNE SNYDER, XICHENG DAVID SUN, YVONNE YEE MAI YIP, Q. MAY WANG, FRANTZ VICTOR, MARK JOSEPH TEBBE, ROBERT B. PERNI, LUC FARMER
-
Publication number: 20120063993Abstract: Disclosed are compounds that include two or more haptens conjugated by a spacer or a carrier. The haptens may include diethylenetriaminepentaacetate (DTPA), histimine-succinyl-glutamine (HSG), or combinations of DTPA and HSG. The compound also includes an effector molecule which may be conjugated to one or more of the haptens, the spacer/carrier, or both. The effector molecule may be conjugated by a number of linkages including an ester linkage, an imino linkage, an amino linkage, a sulfide linkage, a thiosemicarbazone linkage, a semicarbazone linkage, an oxime linkage, an ether linkage, or combinations of these linkages. Also disclosed are methods of synthesizing the compounds and/or precursors of the compounds.Type: ApplicationFiled: June 12, 2008Publication date: March 15, 2012Applicant: IMMUNOMEDICS, INC.Inventors: William J. McBride, David M. Goldenberg, Carl Noren, Hans J. Hansen
-
Publication number: 20120058084Abstract: The present invention relates to a pharmaceutical composition comprising a water-soluble polymeric carrier linked prodrug of interferon alpha, wherein the prodrug is capable of releasing free interferon alpha, wherein the release half life under physiological conditions is at least 4 days. The invention further relates to prodrugs for said pharmaceutical composition and their use for treating, controlling, delaying or preventing a condition that can benefit from interferon alpha treatment, such as hepatitis C.Type: ApplicationFiled: March 4, 2010Publication date: March 8, 2012Applicant: ASCENDIS PHARMA ASInventors: Harald Rau, Silvia Kaden-Vagt
-
Publication number: 20120058085Abstract: This invention relates to derivatives of 1-(p-chlorobenzyl)-2-(1-pyrrolidinylmethyl)benzimidazole according to Formula I wherein at least one Y is deuterium described herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of hepatitis C virus (HCV) RNA replication.Type: ApplicationFiled: May 14, 2010Publication date: March 8, 2012Inventors: Rose A. Persichetti, Julie F. Liu, Adam Morgan
-
Publication number: 20120052046Abstract: Phosphoramidate compounds derived from guanine bases having enhanced therapeutic potency are provided, and these compounds in particular have enhanced potency with respect to treatment of viral infections, such as hepatitis C virus. Pharmaceutical compositions, methods of preparing the compounds, and methods of using the compounds and compositions to treat viral infections are also provided.Type: ApplicationFiled: January 11, 2010Publication date: March 1, 2012Inventors: Stanley Chamberlain, Jeff Hutchins, Karolina Madela, Christopher McGuigam, John Vernachio, Mohamed Aljarah, Arnaud Gilles
-
Publication number: 20120045413Abstract: The inventors have treated human patients for warts by intralesional injection of Candida antigen to induce a delayed-type hypersensitivity response in the patients. This creates an immune response that recognizes the antigens of the human papilloma virus (HPV) found in and causing the warts. It was found that the patients showed a response to HPV type 57 L1 peptide 380-412 (a peptide consisting of amino acid residues 380-412 of the protein L1) and HPV type 57 protein E4 (E4 10-30). One embodiment of the invention provides a pharmaceutical composition comprising a polypeptide comprising (a) L1 380-412 (SEQ ID NO:3) or a fragment of at least 8 residues of SEQ ID NO:3 or (b) E4 10-30 (SEQ ID NO:4) or a fragment of at least 8 residues of E4 10-30 (SEQ ID NO:4), wherein the composition is immunogenic in humans.Type: ApplicationFiled: August 11, 2011Publication date: February 23, 2012Inventors: Mayumi Nakagawa, Kevin Kim, Thomas Horn
-
Publication number: 20120045415Abstract: The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.Type: ApplicationFiled: June 3, 2011Publication date: February 23, 2012Applicant: Vertex Pharmaceuticals IncorporatedInventors: Lindsay McNair, John McHutchison
-
Publication number: 20120045394Abstract: The present invention concerns methods and compositions for in vivo and in vitro targeting. A large number of targeting peptides directed towards human organs, tissues or cell types are disclosed. The peptides are of use for targeted delivery of therapeutic agents, including but not limited to gene therapy vectors. A novel class of gene therapy vectors is disclosed. Certain of the disclosed peptides have therapeutic use for inhibiting angiogenesis, inhibiting tumor growth, inducing apoptosis, inhibiting pregnancy or inducing weight loss. Methods of identifying novel targeting peptides in humans, as well as identifying endogenous receptor-ligand pairs are disclosed. Methods of identifying novel infectious agents that are causal for human disease states are also disclosed. A novel mechanism for inducing apoptosis is further disclosed.Type: ApplicationFiled: November 1, 2011Publication date: February 23, 2012Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Wadih Arap, Renata Pasqualini
-
Patent number: 8119116Abstract: The present invention relates to methods of treating a cancerous tumor using selective inhibitors of ATP production. The present invention also relates to pharmaceutical preparations comprising such inhibitors and methods for administering them intraarterially directly to a tumor, as well as methods for identifying compositions that selectively inhibitor ATP production for use in the invention.Type: GrantFiled: January 16, 2009Date of Patent: February 21, 2012Assignee: John Hopkins University School of MedicineInventors: Young Hee Ko, Jean-Francois Geschwind, Peter L. Pedersen
-
Publication number: 20120039980Abstract: Methods of preventing adhesion between issues are provided that utilizes in situ crosslinked biomaterials. The biomaterial contains at least the crosslinked product of two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked compositions include preventing adhesions following surgery or injury, and preventing scar tissue formation.Type: ApplicationFiled: October 24, 2011Publication date: February 16, 2012Inventors: George Y. Daniloff, Louis C. Sehl, Olof Mikael Trollsas, Jacqueline Schroeder, David M. Gravett, Philip M. Toleikis
-
Publication number: 20120039850Abstract: The invention relates to combination therapies for the treatment of hepatitis C virus with telaprevir and pegylated interferon alfa-2a with or without ribavirin. The invention relates to the treatment of patients with bridging fibrosis infected with HCV using the combination therapy.Type: ApplicationFiled: August 11, 2011Publication date: February 16, 2012Applicants: Janssen Pharmaceutica NV, Vertex Pharmaceuticals IncorporatedInventors: Lindsay McNair, Robert S. Kauffman, John J. Alam, Ramon Polo, Gaston Rafael Picchio, Maria Gloria Beumont
-
Publication number: 20120039805Abstract: The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial; lymphomas, sarcomas, melanomas, and the like, comprising determining the level of caveolin-1 and/or caveolin-2 in stromal cells adjacent to a neoplasm.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Inventors: Michael P. Lisanti, Federica Sotgia, Richard G. Pestell
-
Publication number: 20120039844Abstract: An improved composition and method for reducing the formation of oxygen radicals in mononuclear phagocytes is disclosed. Also provided is a method of protecting NK cells from oxidative damage inflicted by radicals produced by mononuclear phagocytes by administering a histamine metabolite, N-alpha-methylhistamine dihydrochloride. Use of N-alpha-methylhistamine dihydrochloride for enhancing the NK cell response to IL-2 is likewise detailed.Type: ApplicationFiled: April 9, 2010Publication date: February 16, 2012Inventor: Kristoffer Hellstrand
-
Publication number: 20120039848Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: August 11, 2011Publication date: February 16, 2012Inventors: Yao-Ling Qiu, Xiaowen Peng, Ce Wang, Yat Sun Or
-
Publication number: 20120039797Abstract: The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.Type: ApplicationFiled: September 26, 2011Publication date: February 16, 2012Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Hans J. Hansen
-
Patent number: 8114395Abstract: This invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and therefore is useful to prevent and treat viral diseases and cancers. This invention also provides an artificial gene which codes for the super-compound interferon or its equivalent. Finally, this invention provides methods to produce recombinant super-compound interferon or its equivalent and various uses of said interferon.Type: GrantFiled: April 18, 2008Date of Patent: February 14, 2012Assignee: Sichuan Biotechnology Research CenterInventors: Guangwen Wei, Rongbing Guo, Renhuai Zhang
-
Publication number: 20120034187Abstract: Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: ApplicationFiled: October 21, 2011Publication date: February 9, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Montse LLINAS-BRUNET, Murray BAILEY, Punit BHARDWAJ, Josee BORDELEAU, Pasquale FORGIONE, Elise GHIRO, Vida GORYS, Nathalie GOUDREAU, Sylvie GOULET, Teddy HALMOS, Jean RANCOURT
-
Patent number: 8110182Abstract: The present invention consists of the combination of Interferon alpha and C-Phycocyanin (IFN-?/C-Phyco) for obtaining a pharmaceutical preparation for autoimmune disease, allergy and cancer treatments. The anti-inflammatory, immunomodulator, antioxidant, anti-viral, anti-proliferative and anti-tumoral effects, associated to the regulatory T cell inducer effect demonstrated in this invention is the rationale for the use of the IFN-?/C-Phyco combination in these diseases.Type: GrantFiled: October 30, 2006Date of Patent: February 7, 2012Assignee: Centro de Ingenieria Genectica y BiotecnologiaInventors: Giselle Penton Rol, Majel Cervantes Llanos, Eduardo Penton Arias, Diana Garcia del Barco Herrera, Carmen Maria Valenzuela Silva, Pedro Antonio Lopez Saura, Gerardo Enrique Guillen Nieto
-
Publication number: 20120027723Abstract: The present invention relates to taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration. More particularly the invention relates to a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis for the prevention and treatment of a disease associated with retinal ganglion cell degeneration.Type: ApplicationFiled: July 26, 2011Publication date: February 2, 2012Inventor: Serge Picaud
-
Publication number: 20120027722Abstract: The present invention relates to methods and compositions for the treatment or prevention of hepatitis C virus comprising the administration of a combination of anti-hepatitis C virus antibodies and a-interferon.Type: ApplicationFiled: December 17, 2009Publication date: February 2, 2012Inventors: Sharookh Kapadia, Arvind Patel, David J. Matthews, David G. Williams
-
Publication number: 20120027846Abstract: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.Type: ApplicationFiled: July 28, 2011Publication date: February 2, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Brian AGNEW, David GRAHAM, Upinder SINGH, Scott GRECIAN
-
Patent number: 8105608Abstract: A method and pharmaceutical composition are provided for enhancing the endogenous immune response-mediated elimination of a population of pathogenic cells in a host animal wherein the pathogenic cells preferentially express, uniquely express, or overexpress a binding site for a particular ligand. The invention comprises administering the ligand conjugated to an immunogen to a host animal harboring the population of pathogenic cells. Antibodies, preexisting or administered to the host animal to establish a passive immunity, directed against the immunogen bind to the ligand-immunogen conjugate resulting in elimination of the pathogenic cells by the host's immune response.Type: GrantFiled: November 16, 2005Date of Patent: January 31, 2012Assignee: Purdue Research FoundationInventors: Philip Stewart Low, Yingjuan Lu
-
Publication number: 20120020923Abstract: Invented is a method of treating viral diseases, particularly hepatitis C, in a human, in need thereof which comprises the administration of a combination of therapeutically active agents selected from a TPO receptor agonist and an antiviral therapy selected from: an alpha interferon, ribavirin, a ribavirin analog and an HCV antiviral to such human.Type: ApplicationFiled: July 26, 2011Publication date: January 26, 2012Inventors: Connie L. Erickson-Miller, Julian Jenkins, Dickens Theodore
-
Publication number: 20120021036Abstract: The invention provides nanostructures or products of manufacture for use as ex vivo or in vivo composition (e.g., a drug, or a therapeutic, diagnostic or imaging reagent) delivery vehicles. In one aspect, the invention provides nanoparticles comprising several compartments which in unison function as a composite nanostructure. In one embodiment, the nanoparticles of the invention comprise a combination of polymer core/lipid bilayer interface which incorporate covalently attached lipid-vascular targeting ligands. These composite nanoparticles can deliver highly effective and selective payloads for diagnostic, prophylactic or therapeutic applications.Type: ApplicationFiled: January 14, 2010Publication date: January 26, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Bharat Majeti, Eric Murphy, Wolfgang Wrasidlo, David Cheresh
-
Publication number: 20120014869Abstract: Provided are MUC 18 targeting peptides which may be used, e.g., to therapeutically target B-I lymphocytes to reduce the influence of these cells on the metastatic potential of melanoma cells and/or to target cancerous cells, including certain melanoma and leukemia cells. MUC 18 targeting peptides may be comprised in fusion constructs, imaging constructs, and/or therapeutic constructs such as fusion constructs which may be used for diagnosing or treating a cancer.Type: ApplicationFiled: October 15, 2009Publication date: January 19, 2012Applicant: The Board of Regents of the Univesity of Texas SystemInventors: Fernanda Staquicini, Renata Pasqualini, Wadih Arap
-
Publication number: 20120014905Abstract: Novel compounds of the general formula (I): in which X represents a polymer; Q represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; each of R1 and R2 independently represents a hydrogen atom or a C1-4alkyl group; and either Z1 represents a protein or a peptide linked to CR2 via a nucleophilic moiety, and Z2 represents a molecule linked to CR2 via a nucleophilic moiety, or Z1 and Z2 together represent a single group derived from a protein or peptide linked to CR via two nucleophilic moieties.Type: ApplicationFiled: March 4, 2010Publication date: January 19, 2012Inventors: Antony Robert Godwin, Stephen James Brocchini
-
Publication number: 20120014914Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt, or mixtures thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.Type: ApplicationFiled: September 21, 2011Publication date: January 19, 2012Applicant: Vertex Pharmaceuticals IncorporatedInventors: Luc J. Farmer, Robert B. Perni, Govinda Rao Bhisetti, Keith P. Wilson
-
Publication number: 20120014919Abstract: A method is provided for treating conditions that are susceptible of treatment with a cytokine wherein certain physiological processes normally associated with cytokine administration (e.g. the induction of SOCS 1 and/or SOCS 3) are diminished or eliminated. The method comprises continuously administering a controlled dose of a cytokine to an individual afflicted with a condition susceptible of treatment with the cytokine.Type: ApplicationFiled: August 30, 2011Publication date: January 19, 2012Applicant: MEDTRONIC, INC.Inventors: Wiliam P. Van Antwerp, Poonam S. Gulati
-
Publication number: 20120009151Abstract: Disclosed herein are novel triazines and related compounds, the synthesis thereof, and compositions, including pharmaceutical compositions, comprising the novel triazines and related compounds. Such novel triazines and related compounds function to inhibit or block entry of viruses of the Flaviviridae family, including Hepatitis C virus (HCV), into cells that are susceptible to virus infection. These compounds are useful for the treatment, therapy and/or prophylaxis of viral diseases and infection, including HCV infection.Type: ApplicationFiled: December 19, 2008Publication date: January 12, 2012Applicant: Progenics Pharmaceuticals, Inc.Inventors: Amy Qi Han, Glen A. Coburn, Kathleen P. Provoncha, Yakov Rotshteyn
-
Publication number: 20120009140Abstract: The invention relates to a composition which induces, in a host, a cytotoxic cell response directed against cells expressing an antigen, in particular tumour cells, and which comprises red blood cells containing said antigen. These red blood cells may be in the form of an immune complex with an immunoglobulin, in particular IgG, which recognizes an epitope at the surface of the red blood cells, and/or be heat-treated or chemically treated so as to promote phagocytosis of said red blood cells by dendritic cells. As a variant, the red blood cells may be xenogenic red blood cells. The invention also relates to a therapeutic especially anti-tumour vaccine containing such a composition.Type: ApplicationFiled: August 8, 2008Publication date: January 12, 2012Applicant: Erytech PharmaInventors: Yann Godfrin, Alice Banz
-
Publication number: 20120009150Abstract: The present invention relates to pharmaceutical compositions for treating virus infections and/or diseases caused by virus infections comprising at least a diaryl urea compound optionally combined with at least one additional therapeutic agent. Useful combinations include e.g. BAY 43-9006 as a diaryl urea compound.Type: ApplicationFiled: September 20, 2011Publication date: January 12, 2012Inventors: Olaf WEBER, Bernd Riedl
-
Publication number: 20120009149Abstract: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-?2b.Type: ApplicationFiled: August 29, 2011Publication date: January 12, 2012Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Publication number: 20120003296Abstract: The invention relates to a method of insulin eye drops for treating dry eye syndrome due to any and all etiological factors (Keratoconjunctivitis sicca), including Sjogren's syndrome, Meibomian gland dysfunction (MGD) and other glandular malfunction in the eye lids, lacrimal glands, cornea, conjunctiva, and exposed scleral surface of the eye. It is treated with Insulin and/or IGF-I with or without known anti-dry eye syndrome therapeutic, pharmaceutical, biochemical and biological agents or compounds.Type: ApplicationFiled: July 1, 2010Publication date: January 5, 2012Inventors: Totada R. Shantha, Erica Maya Shantha, Jessica Gowramma Shantha
-
Patent number: 8088368Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: May 12, 2010Date of Patent: January 3, 2012Assignee: Gilead Sciences, Inc.Inventors: Hongyan Guo, Darryl Kato, Thorsten A. Kirschberg, Hongtao Liu, John O. Link, Michael L. Mitchell, Jay P. Parrish, Jianyu Sun, James Taylor, Elizabeth M. Bacon, Eda Canales, Aesop Cho, Choung U. Kim, Jeromy J. Cottell, Manoj C. Desai, Randall L. Halcomb, Scott E. Lazerwith, Richard L. Mackman, Hyung-Jung Pyun, Joseph H. Saugier, James D. Trenkle, Winston C. Tse, William J. Watkins, Lianhong Xu
-
Publication number: 20110318306Abstract: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody.Type: ApplicationFiled: January 25, 2011Publication date: December 29, 2011Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Publication number: 20110315575Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.Type: ApplicationFiled: August 29, 2011Publication date: December 29, 2011Applicants: The Board of Trustees of the University of Illinois, Spectrum Pharmaceuticals, Inc.Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
-
Patent number: 8084022Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example interferons, such as interferon-alpha, interferon-beta, interferon-gamma, and variants thereof.Type: GrantFiled: March 17, 2008Date of Patent: December 27, 2011Assignee: Aegis Therapeutics, LLCInventor: Edward T. Maggio
-
Publication number: 20110311485Abstract: The present disclosure relates to 1, 2, 4 oxadiazole derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the S1P1 receptors.Type: ApplicationFiled: December 15, 2009Publication date: December 22, 2011Applicant: ALMIRALL S.A.Inventors: Victor Giulio Matassa, Nuria Aguilar Izquierdo, Marta Mir Cepeda, Marta Carrascal Riera, Silvia Fonquerna Pou, Aranzazu Cardus Figueras, Julio Cesar Castro Palomino Laria, Montserrat Erra Sola
-
Publication number: 20110311482Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.Type: ApplicationFiled: December 13, 2010Publication date: December 22, 2011Inventors: Xiangdong Alan Wang, Li-Qiang Sun, Sing-Yuen Sit, Ny Sin, Paul Michael Scola, Yan Chen
-
Publication number: 20110311474Abstract: The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.Type: ApplicationFiled: December 1, 2010Publication date: December 22, 2011Applicant: ABBOTT LABORATORIESInventors: Neil WISHART, Maria A. ARGIRIADI, David J. CALDERWOOD, Anna M. ERICSSON, Bryan R. FIAMENGO, Kristine E. FRANK, Michael FRIEDMAN, Dawn M. GEORGE, Eric R. GOEDKEN, Nathan S. JOSEPHSOHN, Biqin C. LI, Michael J. MORYTKO, Kent D. STEWART, Jeffrey W. VOSS, Grier A. WALLACE, Lu WANG, Kevin R. WOLLER